Therapies – discovery and development (1)
B174 – B201
- B174: Chemotherapy for bladder cancer: a United Kingdom practice survey
- B175: Is adjuvant chemotherapy adequate as a general treatment approach to cancer? A qualitative systematic review
- B176: The Royal Marsden Hospital (RMH) Prognostic Score for Phase I Studies
- B177: The aromatase inhibitor letrozole enhances the effects of doxorubicin and docetaxel in an MCF7 cell line model
- B178: Enhance cytoxoxicity of gemcitabine to resistant cancer cell lines by disulfiram, an antialcoholism drug
- B179: DNA polymerase beta modulates sensitivity and resistance of colon cancer cells to oxaliplatin via DNA damage repair
- B180: Preclinical development strategy to obtain regulatory approval for a Phase 1 trial using adoptive transfer of autologous T-cells expressing the chimeric immune receptor MFE23-CD3ζ in patients with advanced carcinoembryonic antigen positive malignancies
- B181: Imatinib mesylate delays tumour regrowth after single dose CA-1-P therapy in LS174T but not SW1222 xenografts
- B182: Imatinib mesylate augments the selective targeting to tumour of radiolabeled anti-CEA antibodies from non-tumour tissues in LS174T and SW1222 xenografts
- B183: OXi4503 shows efficacy as a single agent in colorectal liver metastases in nude mice, and potential for enhancing antibody-targeted therapies
- B184: HOX transcription factors as potential therapeutic targets in non-small cell lung cancer
- B185: Preclinical development of obatoclax therapy for small cell lung cancer
- B186: The BH3 peptidomimetic obatoclax restores absent mitochondrial death signals in cisplatin resistant non-small cell lung cancer
- B187: Reversal of Bortezomib Resistance by a MCL-1/A1 targeting Small Molecule BH3 Mimetic in Mesothelioma
- B188: Development of cellular immune responses against PAX5; a novel target for cancer immunotherapy
- B189: Betastatin, a novel fragment of human fibrinogen, is a potent inhibitor of activated endothelial cells
- B190: Gamma secretase as a potential therapeutic target in pancreatic adenocarcinoma
- B191: A rapid and sensitive assay to detect RET M918T mutations in tumor samples from patients with sporadic medullary thyroid cancer
- B192: In vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia
- B193: VEGF autocrine signalling maybe involved in proliferation of tumour initiating cells
- B194: Activity of rapamycin against fresh human tumour and normal cells ex vivo
- B195: GMP production of therapeutic T-cells for a Cancer Research UK phase I clinical trial of autologous tumour antigen-specific T-cells for patients with advanced CEA positive tumours
- B196: Development of potent water-soluble inhibitors of the DNA-dependent protein kinase (DNA-PK)
- B197: Novel quantum dot-photosensitizer nanocomposites and their potential in photodynamic therapy of cancer
- B198: Immunological targeting of the cancer phosphoproteome
- B199: Targeting the plekstrin homology domain
- B200: Novel cambinol analogues as sirtuin inhibitors: design, synthesis and biological evaluation
- B201: Generation of a fully human anti-CD20 antibody with improved effector function, through the combined use of Xenomouse and ribosome display technologies
